Last mentioned: Mar 19, 2026
Stock Volatility
RCKT shares decline 4.4% amid sector-wide growth stock pressure and regulatory uncertainty.
EU Complaint
Broadcom faces formal competition complaint from the EU regarding VMware.
SEC Filing 8-K
Company enters into a new material definitive agreement and terminates a previous facility.
SEC Filing
RCKT files notice of entry into/termination of material definitive agreements.
RCKT Earnings
Rocket Pharmaceuticals reports Q4 and Full Year 2025 financial results.
FY 2025 Earnings
Rocket Pharmaceuticals reports full-year 2025 results and provides pipeline updates.
Rocket Pharmaceuticals (RCKT) shares fell 4.4% following recent clinical and financial updates, while Broadcom (AVGO) slipped 1.1% as the company faces a new EU antitrust complaint regarding its VMware acquisition.
Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.